Takeda to cut 2,800 jobs as it absorbs Nycomed

Wednesday, January 18, 2012 12:21 PM

Osaka, Japan-based Takeda Pharmaceutical plans to consolidate its R&D site operations and cut its workforce by 2,800 to integrate legacy Nycomed operations, strengthen its presence in more than 70 countries, adapt to changing market conditions and maintain a focus on growth through innovation and culture.

The company will align Nycomed’s former operation structures and processes with the Takeda global headquarters in Japan and the newly defined organizations of the Chief Commercial Officer, headquartered in Zurich, Switzerland, and Chief Medical & Scientific Officer, headquartered in Deerfield, Illinois, and its expanded affiliate network worldwide.

“The combination of Takeda and Nycomed, which we acquired Sept. 30, 2011, brought together Takeda’s strong presence in the Japanese and U.S. markets with the legacy Nycomed business infrastructure in Europe and high-growth emerging markets,” said Yasuchika Hasegawa, president and CEO of Takeda Pharmaceutical. “While our combined operations in more than 70 countries are more complementary than overlapping, there are a number of areas where we will need to make changes to ensure efficient and flexible operations moving forward.”

Takeda will shift from a product portfolio centered on mature, high-selling products to a more diverse portfolio focused on new products. The combined company has an active commercial presence in metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management.

To meet its goals, Takeda plans consolidation of a number of sites and functions, including the potential merger or liquidation of subsidiaries mainly in Europe, and a reduction of workforce in both Europe and the U.S., primarily within Takeda Pharmaceuticals North America. Takeda plans to cut approximately 2,800 positions (2,100 mainly in Europe and 700 in the U.S.) over the next five years, across R&D, commercial, operations and G&A functions.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 22

Roche/Genentech plans pilot trial to measure patientpreference for participating at home v. at study site

Bipartisan 21st Century Cures initiative prepares to draft legislation to accelerate biomedical R&D, lower cost

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs